

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

July 16, 2019

10:00am- 12:00 pm

OPEN SESSION AGENDA

Open Session Agenda

<p>0716-O-01</p>	<p><u>Welcome & Introductions</u></p> <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <ul style="list-style-type: none">(a) On the implementation and evaluation of the Program;(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and(f) Regarding the design and implementation of educational courses for:<ul style="list-style-type: none">(1) Persons who are authorized to access the prescription monitoring information;(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.	
------------------	---	--

0716-O-02	<p><u>Approval of April 2019 PDMP Advisory Committee Meeting Minutes</u> (a) Minutes from April 30, 2019 Meeting</p>	
0716-O-03	<p><u>Report from Attorney Advisor</u> (a) PDMP Legislative Update (b) Gabapentin added as drug of concern June 7, 2019 (link)</p>	
0716-O-04	<p><u>Program Updates</u> (a) Program Statistics (b) Progress on Mandatory Registration (c) Past and Future Outreach Activities (d) Plans for a PDMP user survey (e) Unsolicited reports to prescribers (f) Update: PDMP Annual Report</p>	
0716-O-05	<p><u>Grant Updates</u> (a) Clinical Coordinator and Outreach Coordinator (b) Districtwide Gateway Integration (c) NarxCare Package (d) Opioid Indicator Dashboard launched June 14, 2019 (link) (e) Opioid Awareness Communications Campaign (link)</p>	
0716-O-06	<p><u>PDMP Best Practice Checklist Updates and Discussion</u></p>	
0716-O-07	<p><u>Action Items</u></p> <ul style="list-style-type: none"> • Future meeting dates: <ul style="list-style-type: none"> ○ October 15, 2019 ○ January 14, 2020 ○ April 14, 2020 ○ July 14, 2020 	
0716-O-08	<p>Other news/highlights from Committee members</p>	
<p>Comments from the Public</p>		
<p>Motion to Adjourn the Open Session</p>	<p>Madam Chair, I move that the Committee close the Open Public session portion of the meeting.</p> <p style="text-align: center;">(Roll Call Vote)</p>	

This concludes the Public Open Session of the meeting.

Open Session Meeting Adjourned at __:__ PM